Aurobindo Pharma Ltd · NSE:AUROPHARMA
Aurobindo Pharma — Investor Presentation (May 2016)
26 slides from Aurobindo Pharma's investor presentation, May 2016
Slide 1: Investor Presentation May 2016
INVESTOR PRESENTATION May 2016
Slide 2: Disclaimer
Disclaimer This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these
Slide 3: Company Overview
Company Overview Among the Top-5 listed pharmaceutical companies from India Top 10 Therapy Segments by sales(1) and market capitalization(2) Category Size (US$ Bn) APL’s presence Well entrenched US portfolio of 398 filed ANDAs including Oncology 74.5 215 final approved; 49 final approved in FY
Slide 4: The Journey So Far…
The Journey So Far… Creation of a leading vertically integrated platform Acquired formulations Commencement of export First approval of Controlled Acquired Western European facility in USA and of APIs Substance formulations in commercial operations from Actavis Pharmacin in Netherlands Ini
Slide 5: Our Business Segments
Our Business Segments US EU Ranked 7th* Rx supplier as per Among top 15** Gx companies IMS total prescription dispensed by sales Differentiated pipeline with new Focus markets are France, launches including injectables, Germany, Netherlands, Spain, ophthalmics , speciality products UK, Portu
Slide 6: US Business Overview
US Business Overview Aurobindo USA AuroMedics AuroLife Pharma AuroHealth Natrol Oral Rx Injectables Manufacturing / Pharma OTC Nutraceuticals R&D Cumulative ANDA Filings and Approvals Gross Revenue (INR Cr) 52% CAGR Tentative Approvals include 21 ANDAs approved under PEPFAR Unit wise ANDA Filings as
Slide 7: US: Expanding Portfolio Mix Towards High-value Products
US: Expanding Portfolio Mix Towards High-value Products Portfolio mix is complemented with the introduction of high-value products Future pipeline to include Oncology, Hormones, Depot injections, Inhalers, Patches and Films *Does not include the addressable market of the products approved under PEPF
Slide 8: Natrol
Natrol Amongst the top 20 branded nutraceuticals companies in US Diverse Customer Base with long term relationships with key distribution and retail partners Strong customer partnerships across multiple distribution channels with growth potential within each channel R&D capabilities in new i
Slide 9: EU Business Overview
EU Business Overview France Germany Netherlands Spain UK Portugal Italy Romania Belgium India’s Leading Gx company with strong footprint in Europe Gross Sales (INR Cr) Operations in 9 countries with full fledged sales force & support infrastructure 88% CAGR Significant presence and position in
Slide 10: EU: Portfolio Mix Across Channels
EU: Portfolio Mix Across Channels Sales split by Channel Sales split by Therapeutic Profile Sales split by Dosage Forms Channels Gx BGx Hx TGx Germany, Spain Geographies All 9 countries 7 countries All 9 countries & Netherlands 761 (primarily 343 (predominantly 765 (including Gx # of Products 34 tab
Slide 11: ARV Business Overview
ARV Business Overview Focus on global tenders floated by Multi-Lateral Organizations like Global Fund, USAID/PEPFAR and Country specific MOH tenders; Gross Sales (INR Cr) currently caters to 2.2 million HIV+ patients 17% CAGR Well integrated supply chain management services and logistics for ARV
Slide 12: Emerging Markets Business Overview
Emerging Markets Business Overview Focus markets include Brazil, South Africa, Ukraine and Gross Sales (INR Cr) Mexico 18% CAGR Geographic diversification through expansion into selective markets of Asia Pacific, Africa, Middle East etc Opportunity to Leverage Build branded generics presence
Slide 13: The Base Business : API
The Base Business : API Gross Sales (INR Cr) Amongst the most vertically integrated generic pharma platforms with API integration for around 75% of its products; offers cost competitiveness and high process chemistry skills coupled with 4% CAGR commitment to quality Quality & Reliability of supp
Slide 14: Consolidated Financial Performance
Consolidated Financial Performance Q4 Q4 Q3 Value INR Cr FY16 FY15 % Chg FY16 FY15 FY16 Formulations 3,011 2,517 2,837 11,166 9,559 16.8% API 775 676 695 2,884 2,706 6.6% Formulations % of sales 80% 79% 80% 79% 77.9% Net Operating Income 3,747 3,162 3,495 13,896 12,121 14.6% 2,120 1,788 1,942 7,739
Slide 15: Financial Performance
Financial Performance Sales (INR Cr) EBITDA & PAT Margin (%) EPS (INR/Share) Gross Block & Fixed Asset Turnover Average ROE & ROCE % Net Debt/Eq & Net Debt/EBITDA Gross Block is calculated as Tangible Assets + Intangible Assets-Goodwill 14
Slide 16: Debt Profile
Debt Profile Fx Loan US$ Mn Debt as on (INR Cr) Mar-14 Mar-15 Mar-16 Closing Rate1 US$ = INR 59.92 62.50 66.26 609 691 688 Fx Loan restated in INR 3,651 4,355 4,600 Rupee Loan 53 50 106 Sales Tax Deferment 65 55 42 Gross Debt 3,769 4,460 4,708 Cash Balance 181 471 840 Net Debt 3,588 3,989 3,867 Net
Slide 17: New Business and Technology Initiatives to Support Growth
New Business and Technology Initiatives to Support Growth Peptides Manufacturing peptides from short to long chain molecules supporting mg to kg scale Highly Experienced team of scientists; developed technologies for over 10 products Three DMFs filed; work ongoing on more products Forward in
Slide 18: Key Investments for Future Growth
Key Investments for Future Growth Brownfield Expansions ► New dedicated block for lypholized vials at Unit IV (General Injectable facility), India ► New finished dosage formulations blocks at Unit VII (SEZ), India ► New API blocks at Unit XI, India ► Substantial capacity expansion at AuroLife, USA G
Slide 19: Way Forward
Way Forward Market share gain for existing products and introduction of new products (currently 107 ANDAs* Orals under review) Specialty 40* ANDA filings under review for injectables with a pipeline of Oncology, Peptides and Penem USA Expand penetration of existing OTC products and capability to cap
Slide 20: Annexure
Annexure 19
Slide 21: Sales Break-Up
Sales Break-Up FY14 FY15 FY16 INR Bn Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 USA 6.2 7.3 9.3 11.2 11.2 11.7 12.0 13.4 14.3 14.8 15.7 16.7 Europe 1.7 1.7 1.5 1.8 8.0 7.7 8.6 7.7 7.4 7.6 7.8 8.4 Emerging Market 1.1 0.9 1.3 1.3 1.4 1.6 1.3 1.4 1.7 1.7 1.8 1.8 ARV 1.9 2.3 2.2 1.9 2.2 1.4 3.3 2.7 3.0 2.7 3.1
Slide 22: 5 Year Financial Snapshot
5 Year Financial Snapshot Value INR Bn FY12 FY13 FY14 FY15 FY16 Net Operating Income 46.3 58.6 81.0 121.2 138.9 Gross margin % of operating income 45.5% 48.9% 55.5% 54.6% 55.7% EBITDA (before Fx and other income) % 13.2% 15.2% 26.4% 21.2% 23.1% to Operating income Depreciation / Amortization 2.0 2.5
Slide 23: Filing details as on 31st March 2016
Filing details as on 31st March 2016 As at As at As at As at Category Approvals Mar 13 Mar 14 Mar 15 31.03.16 Formulations 251 (FA: 215, US* 269 336 376 398 TA:36) 1,328 Dossiers Europe** 1,341 1,542 1,756 2,224 (149 products) 167 Registrations SA** 314 334 345 374 (84 products) Canada*** 49 72 83 1
Slide 24: Extensive Manufacturing Base with High Quality Control and Compliance
Extensive Manufacturing Base with High Quality Control and Compliance Finished Dose Formulations Active Pharma Ingredients Site Product Capabilities Site Product Capabilities Unit III Non antibiotics, ARVs / Orals Unit I CVS, CNS, Anti-Allergics, Non-Sterile Unit IV Injectables (Non-antibiotics)&Oph
Slide 25: Shareholding Pattern
Shareholding Pattern As on As on As on As on Group 31.03.13 31.03.14 31.03.15 31.03.16 Non-Promoter Holding 46.1% Promoter Group 54.9% 54.6% 54.0% 53.9% FII 16.8% 23.7% 29.6% 27.4% MF / Insurance 13.4% 9.8% 6.2% 7.2% Other Bodies Corporates 5.5% 2.2% 1.6% 2.4% Retail Investors 9.4% 9.7% 8.6% 9.1% To
Slide 26: Thank You
Thank You For updates and specific queries, please visit our website www. aurobindo.com Investor Relations: Deepika Gupta Padhi Phone: +91-40-66725000/5401 +91 98486 67906 Email: [email protected] Corporate Office: Water Mark Building, Level-1, Plot No.11, Survey No. 9, Kondapur, Hitech City, Hyderab